<DOC>
	<DOCNO>NCT00261404</DOCNO>
	<brief_summary>Phase II , open label study patient metastatic melanoma ( stage III IV ) cancer consider curable surgery receive intratumoral injection TNFerade™ plus radiation 4-week treatment , follow 3 year follow-up period .</brief_summary>
	<brief_title>TNFerade™ Biologic Plus Radiation Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient must 18 year old old , able give inform consent . Patients metastatic melanoma ( AJCC stage III IV ) eligible curative surgery candidate experimental therapy . Eligible patient include melanoma involve regional lymph node surround tissue well unresectable cutaneous , subcutaneous , nodal soft tissue metastasis . Patients must one tumor nodules accessible direct injection . Patients metastasis outside treatment field may enrol site metastases limit survival expectancy le 3 month . Patients must unlikely derive significant potential benefit treatment option treatment anticipate study treatment period period two month thereafter . Patient 's Karnofsky performance status must great equal 70 % . Chemotherapy experimental medication within last four week prior Day 1 . Active disease central nervous system . Baseline liver enzyme ( AST , ALT , bilirubin , alkaline phosphatase ) great 3 time upper limit normal . Renal insufficiency ( Serum creatinine great 2.0 mg/dL ) . Coagulopathy ( PT INR &gt; 1.5 PTT ratio &gt; 1.5 patient receive anticoagulant ) . Significant anemia ( e.g . hematocrit &lt; 28 % hemoglobin &lt; 9 g/dL ) . May RBC transfusion , thrombocytopenia ( platelet count le 100,000/μl ) ; leukopenia ( WBC &lt; 3000/μl ; ANC &lt; 1500/μl ) . Patients documented history deep venous thrombosis , pulmonary embolus , cerebrovascular disease , stroke , TIA . Patients history coagulopathy know thrombophillic disorder . Clinical evidence active infection type , include hepatitis B C virus . Pregnant lactating woman . It recommend men woman use condom another barrier method birth control least 2 month follow last administration TNFerade™ biologic form birth control least 1 year . Significant concurrent medical psychiatric illness , opinion investigator , would interfere patient 's ability participate trial Chronic systemic corticosteroid use , orally parenterally administer . Known sensitivity lidocaine , procaine amide local anesthetic ( used topical anesthesia ) . Surgery within last 4 week prior day 1 ( patient ambulatory within 48 hour surgery , patient may consider eligible ) Attempted resection tumor treat , surgery area treat , incomplete heal surgical wound . ( If surgical wound completely heal lesion continue progress , patient may enrol . ) Patients history clinical lymphedema area treat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>